Clinical trials: Overweight or Obesity
Obesity, Obese
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
- Conditions
- Obesity, Obese, Overweight or Obesity
- Trial name
- NCT05616013
- Testing
- Bimagrumab, Semaglutide
- Where
- 26 sites in United States, Australia and 1 more
- Volunteers
- 507 people
- Sponsor
- Eli Lilly and Company
Generalized Lipodystrophy
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months.
- Trial name
- NCT06548100
- Testing
- mibavademab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Regeneron Pharmaceuticals
Type 2 Diabetes Mellitus, Obese
Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes
The purpose of this study is to evaluate the safety, tolerability, and efficacy of ISIS-PTP1BRx + oral antidiabetic drug/s (metformin and/or sulfonylurea) versus placebo + oral antidiabetic drug/s.
- Trial name
- NCT01918865
- Testing
- ISIS-PTP1BRx, daily OAD (metformin and/or sulfonylurea)
- Where
- 21 sites in Argentina, Canada and 1 more
- Volunteers
- 92 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Obesity
A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine
This study will look into a new study medicine called NNC0519-0130 to improve the treatment option for people living with excess body weight or type 2 diabetes or both.
- Trial name
- NCT06642571
- Testing
- NNC0519-0130 B, NNC0519-0130 C
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers
This trial will be conducted in the United States of America (USA). The aim of the trial is to investigate whether the drug is safe, well tolerated and to investigate the efficacy of NNC 0070-0002-0182 for the treatment of…
- Trial name
- NCT00665665
- Testing
- NNC 0070-0002-0182
- Where
- 2 sites in United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese
The purpose of this study is to compare the amount of PF-07081532 in blood after taking two different forms of PF-07081532. This study is seeking participants who are at least 18 years of age and are overweight and/or obese.
- Trial name
- NCT05677867
- Testing
- Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overweight
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
This study is being conducted to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants body weight.
- Trial name
- OASIS 1 (NCT05035095)
- Testing
- Oral semaglutide
- Where
- 56 sites in United States, Canada and 7 more
- Volunteers
- 667 people
- Sponsor
- Novo Nordisk A/S
Apnea, Sleep Disorders
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive…
- Conditions
- Apnea, Sleep Disorders, Overweight and/or Obesity
- Trial name
- VESPER-OSA 2 (NCT07881757)
- Testing
- Berobenatide
- Where
- 2 sites in United States
- Volunteers
- 258 people
- Sponsor
- Pfizer
Chronic Kidney Disease, Type 2 Diabetes
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine.
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes, Obesity
- Trial name
- NCT06131372
- Testing
- Cagrilintide, Semaglutide
- Where
- 129 sites in United States, Argentina and 11 more
- Volunteers
- 626 people
- Sponsor
- Novo Nordisk A/S
Overweight or Obese, Obesity and Overweight
A Trial With EMP16 in Preparation for Late Phase Studies
The goal of this clinical trial is to explore the impact of dietary fibre supplement in the form of Vi-Siblin® S (ispaghula seed coats), together with advice on proper healthy diet, on tolerability during dose-escalation of EMP16…
- Trial name
- POEM (NCT06993428)
- Testing
- EMP16-02 120 mg orlistat/40 mg acarbose, Alli® 60 mg, Vi-Siblin® S
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Empros Pharma AB
Obesity
A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.
The purposes of this study are to: Find out how much of the study drugs are in the blood of healthy subjects after taking multiple doses of VI-0521, metformin and sitagliptan.
- Trial name
- NCT00842400
- Testing
- Metformin, VI-0521, Sitagliptan, Probenecid
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Healthy
Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects
This is a single centre, phase I, randomized, double-blind, placebo-controlled, crossover, dose escalating study of P7435 using single and multiple doses, to be conducted in healthy male and female (Non child bearing) subjects…
- Trial name
- NCT01910571
- Testing
- P7435
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Piramal Enterprises Limited
Overweight, Obesity
Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity
The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity.
- Trial name
- NCT06910839
- Testing
- PF-07976016, PF-06882961
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overweight
A Research Study of VCT220 in Adult Chinese Participants With Obesity
The main purpose of this study is to assess how VCT220 tablets affect the bodyweight in obese or overweight adult participants. Participant will be randomly assigned to the high-dose group, low-dose group, or placebo group.
- Trial name
- NCT06939296
- Testing
- VCT220
- Where
- China
- Volunteers
- 840 people
- Sponsor
- Vincentage Pharma Co., Ltd
Obesity, Overweight
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
This study is open to adults between 18 and 74 years of age and who have a body mass index (BMI) of 30 kg/m2 or more, or a BMI of 27 kg/m2 or more and at least 1 health problem related to their weight.
- Trial name
- NCT07662122
- Testing
- BI 3034701
- Where
- 54 sites in United States, Australia and 4 more
- Volunteers
- 344 people
- Sponsor
- Boehringer Ingelheim
Overweight, Obesity
A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant
The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like birth control tablets, and emptying of the stomach in women not able to become pregnant living with…
- Trial name
- NCT07710729
- Testing
- UBT251, Oral contraceptive, Acetaminophen
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Type 2 Diabetes
EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects
This study will evaluate the safety and efficacy of the EndoBarrier® SANS™ in overweight and obese subjects with type 2 diabetes.
- Trial name
- NCT02443753
- Testing
- EndoBarrier SANS
- Where
- Malaysia
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Morphic Medical Inc.
Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing…
- Trial name
- NCT07685808
- Testing
- Olatorepatide
- Where
- 21 sites in United States
- Volunteers
- 360 people
- Sponsor
- Regeneron Pharmaceuticals
Obesity, Hyperglycemia
The Effect of a Bifidobacterium and Polydextrose on Body Fat Mass
Obesity is a major problem worldwide, and it is related to abnormalities in glucose and lipid metabolism. The purpose of this study is to investigate the effect of a dietary supplement containing probiotic (Bifidobacterium…
- Conditions
- Obesity, Hyperglycemia, Insulin Resistance
- Trial name
- MetSProb (NCT01978691)
- Testing
- Bifidobacterium animalis ssp. lactis 420, Polydextrose
- Where
- 4 sites in Finland
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Danisco
Overweight and Obesity
A Study to Investigate the Safety and Efficacy of TE-8105 in Overweight or Obesity Participants
This is a Phase 2b, randomized, double-blind, placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of TE-8105 in adults with overweight or obesity…
- Trial name
- NCT07857473
- Testing
- TE-8105 MAD Cohort 1, TE-8105 MAD Cohort 2, TE-8105 MAD Cohort 3
- Where
- 2 sites in Australia
- Volunteers
- 204 people
- Sponsor
- Immunwork, Inc.